Philippa Marks

1.6k total citations
32 papers, 787 citations indexed

About

Philippa Marks is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Philippa Marks has authored 32 papers receiving a total of 787 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hepatology, 18 papers in Epidemiology and 12 papers in Infectious Diseases. Recurrent topics in Philippa Marks's work include Hepatitis C virus research (29 papers), Liver Disease Diagnosis and Treatment (14 papers) and Hepatitis B Virus Studies (12 papers). Philippa Marks is often cited by papers focused on Hepatitis C virus research (29 papers), Liver Disease Diagnosis and Treatment (14 papers) and Hepatitis B Virus Studies (12 papers). Philippa Marks collaborates with scholars based in Australia, United Kingdom and United States. Philippa Marks's co-authors include Gregory J. Dore, Jason Grebely, Gail Matthews, Margaret Hellard, Tanya Applegate, Kathy Petoumenos, Marianne Martinello, William D. Rawlinson, Andrew R. Lloyd and John Kaldor and has published in prestigious journals such as Gastroenterology, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Philippa Marks

31 papers receiving 766 citations

Peers

Philippa Marks
Hugues Aumaître France
H. Brett‐Smith United States
A Leentvaar-Kuypers Netherlands
Beth Catlett Australia
Álvaro Mena Spain
Marla A. Shu United States
S. Zaltron Italy
M Roget Spain
Russell Fleischer United States
Maria José Ríos-Villegas Spain
Hugues Aumaître France
Philippa Marks
Citations per year, relative to Philippa Marks Philippa Marks (= 1×) peers Hugues Aumaître

Countries citing papers authored by Philippa Marks

Since Specialization
Citations

This map shows the geographic impact of Philippa Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippa Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippa Marks more than expected).

Fields of papers citing papers by Philippa Marks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippa Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippa Marks. The network helps show where Philippa Marks may publish in the future.

Co-authorship network of co-authors of Philippa Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Philippa Marks. A scholar is included among the top collaborators of Philippa Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippa Marks. Philippa Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fanelli, Giorgia, Philippa Marks, Marco Romano, et al.. (2025). Clinical grade expansion protocol for the manufacture of thymus-derived Treg cells for clinical application. Journal of Translational Medicine. 23(1). 620–620. 1 indexed citations
2.
Hajarizadeh, Behzad, Josh Hanson, James O’Beirne, et al.. (2022). Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort. Journal of Viral Hepatitis. 29(8). 661–676. 9 indexed citations
3.
4.
Hajarizadeh, Behzad, Josh Hanson, James O’Beirne, et al.. (2021). Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. International Journal of Drug Policy. 96. 103422–103422. 16 indexed citations
5.
Catlett, Beth, F. Lamoury, Sahar Bajis, et al.. (2019). Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. Journal of Viral Hepatitis. 26(12). 1423–1430. 13 indexed citations
6.
Dore, Gregory J., Jordan J. Feld, Marianne Martinello, et al.. (2019). Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology. 72(3). 431–440. 26 indexed citations
7.
Lamoury, F., Behzad Hajarizadeh, Camelia Quek, et al.. (2018). Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. Journal of Molecular Diagnostics. 20(5). 621–627. 19 indexed citations
8.
Lamoury, F., Sahar Bajis, Behzad Hajarizadeh, et al.. (2018). Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. The Journal of Infectious Diseases. 217(12). 1889–1896. 94 indexed citations
9.
Lamoury, F., Sahar Bajis, Behzad Hajarizadeh, et al.. (2018). Evaluation of the Xpert fingerstick HCV viral load assay. Journal of Hepatology. 68. S167–S167. 1 indexed citations
10.
Midgard, Håvard, Behzad Hajarizadeh, Evan B. Cunningham, et al.. (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy. 47. 230–238. 25 indexed citations
11.
Grebely, Jason, F. Lamoury, Behzad Hajarizadeh, et al.. (2017). Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. ˜The œLancet. Gastroenterology & hepatology. 2(7). 514–520. 105 indexed citations
12.
13.
Martinello, Marianne, Edward Gane, Margaret Hellard, et al.. (2016). Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study. Hepatology. 64(6). 1911–1921. 36 indexed citations
14.
Lamoury, F., D. Martínez, Behzad Hajarizadeh, et al.. (2016). Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse. Journal of Hepatology. 64(2). S625–S626. 2 indexed citations
15.
Crawford, Dorothy H., Gregory J. Dore, William Sievert, et al.. (2012). Early On-Treatment Viral Load and Baseline Metavir Score: Improved Prediction of Sustained Virological Response in HCV Genotype 1 Patients. Antiviral Therapy. 17(5). 849–854. 1 indexed citations
16.
Matthews, Gail, Son Pham, Margaret Hellard, et al.. (2011). Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases. 52(6). 803–811. 83 indexed citations
17.
Cheng, Wendy, Stuart K. Roberts, Geoffrey W. McCaughan, et al.. (2010). Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology. 53(4). 616–623. 36 indexed citations
18.
Matthews, Gail, Jason Grebely, Margaret Hellard, et al.. (2010). 60 DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN. Journal of Hepatology. 52. S28–S28. 4 indexed citations
19.
Dore, Gregory J., Margaret Hellard, Gail Matthews, et al.. (2009). Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. Gastroenterology. 138(1). 123–135.e2. 115 indexed citations
20.
Grebely, Jason, Kathy Petoumenos, Gail Matthews, et al.. (2009). Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug and Alcohol Dependence. 107(2-3). 244–249. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hugues Aumaître Breakdown of academic impact, for papers by H. Brett‐Smith Breakdown of academic impact, for papers by A Leentvaar-Kuypers Breakdown of academic impact, for papers by Beth Catlett Breakdown of academic impact, for papers by Álvaro Mena Breakdown of academic impact, for papers by Marla A. Shu Breakdown of academic impact, for papers by S. Zaltron Breakdown of academic impact, for papers by M Roget Breakdown of academic impact, for papers by Russell Fleischer Breakdown of academic impact, for papers by Maria José Ríos-Villegas
Rankless by CCL
2026